Linagliptin, another DPP4 inhibitor, was suggested to have a cardioprotective role through FGF-2/EGR-1 pathway in mice with dietary obesity, and capillary rarefaction was suggested to be important in this process [55]. Here, DPP4 is linked to obesity disorder.